Evidence map›Paper›PMID 34159336›Full record

ArticlebioRxiv : the preprint server for biology2021

Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning Strategy.

Lue Ping Zhao, Terry P Lybrand, Peter B Gilbert, Thomas R Hawn, Joshua T Schiffer, Leonidas Stamatatos, Thomas H Payne, Lindsay N Carpp, Daniel E Geraghty, Keith R Jerome

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lue Ping ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA.
Terry P LybrandQuintepa Computing LLC; Nashville, TN, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA.
Thomas R HawnDepartment of Medicine, University of Washington School of Medicine; Seattle, WA, USA.
Joshua T SchifferVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA.
Leonidas StamatatosVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA.
Thomas H PayneDepartment of Medicine, University of Washington School of Medicine; Seattle, WA, USA.
Lindsay N CarppVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA.
Daniel E GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle; WA, USA.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA.

Funding

SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

The emergence and establishment of SARS-CoV-2 variants of interest (VOI) and variants of concern (VOC) highlight the importance of genomic surveillance. We propose a statistical learning strategy (SLS) for identifying and spatiotemporally tracking potentially relevant Spike protein mutations. We analyzed 167,893 Spike protein sequences from US COVID-19 cases (excluding 21,391 sequences from VOI/VOC strains) deposited at GISAID from January 19, 2020 to March 15, 2021. Alignment against the reference Spike protein sequence led to the identification of viral residue variants (VRVs), i.e., residues harboring a substitution compared to the reference strain. Next, generalized additive models were applied to model VRV temporal dynamics, to identify VRVs with significant and substantial dynamics (false discovery rate q-value <0.01; maximum VRV proportion > 10% on at least one day). Unsupervised learning was then applied to hierarchically organize VRVs by spatiotemporal patterns and identify VRV-haplotypes. Finally, homology modelling was performed to gain insight into potential impact of VRVs on Spike protein structure. We identified 90 VRVs, 71 of which have not previously been observed in a VOI/VOC, and 35 of which have emerged recently and are durably present. Our analysis identifies 17 VRVs ∼91 days earlier than their first corresponding VOI/VOC publication. Unsupervised learning revealed eight VRV-haplotypes of 4 VRVs or more, suggesting two emerging strains (B1.1.222 and B.1.234). Structural modeling supported potential functional impact of the D1118H and L452R mutations. The SLS approach equally monitors all Spike residues over time, independently of existing phylogenic classifications, and is complementary to existing genomic surveillance methods.

Identifiers

PMID34159336
PMCPMC8219100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.